OpenAI has quietly taken a stake in Merge Labs, the brain-computer interface (BCI) company launched by OpenAI co-founder and former CEO Sam Altman, marking the AI giant’s first direct move into neurotechnology. The investment, confirmed on January 14, 2026, comes at a time when several major technology companies are racing to develop direct interfaces between the human brain and artificial intelligence systems.

Merge Labs is working on non-invasive BCI technology that aims to offer high-bandwidth, comfortable, and consumer-grade brain signal reading and (eventually) writing capabilities. Unlike Neuralink’s surgically implanted approach, Merge Labs is focusing on external, wearable or near-wearable devices that do not require invasive procedures. The company has not yet revealed detailed product specifications, but early descriptions suggest the goal is to create a seamless bridge between thought and digital interaction.

The partnership is expected to combine OpenAI’s world-leading large language models with Merge Labs’ hardware and neuroscience expertise. Potential applications include thought-based interaction with ChatGPT-style assistants, real-time cognitive augmentation, and new forms of human-AI collaboration. While initial products are likely to focus on wellness, communication assistance, and productivity, long-term ambitions appear to include deeper integration with AI for both consumer and clinical use cases.

Sam Altman, who remains chairman of OpenAI but has been less involved in day-to-day operations since mid-2025, is personally leading Merge Labs. The investment underscores Altman’s continued belief in the convergence of AI and human cognition as one of the most transformative technological frontiers of the coming decades.

Industry observers note that OpenAI’s entry into BCI comes amid growing competition in the space. Neuralink (backed by Elon Musk), Synchron, Blackrock Neurotech, and several university spin-offs are all pursuing different approaches to brain interfacing. OpenAI’s involvement is seen as a major validation of the field’s long-term potential, even as significant technical, ethical, and regulatory hurdles remain.

Neither OpenAI nor Merge Labs has disclosed the exact size of the investment or the ownership stake. However, people familiar with the matter describe it as “material” and indicate that the partnership will involve close technical collaboration rather than merely a financial transaction.

The announcement has already sparked intense discussion in the tech and neuroscience communities about the future of human-AI symbiosis, privacy implications of brain data, and the pace at which consumer-grade brain interfaces might become reality.